Efficacy of peginterferon-α-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C

Liver International

Volumn 30, Issue 4, 2010, Pages 527-537

  Honda, Takashi ^a   Katano, Yoshiaki ^a   Shimizu, Junichi ^a   Ishizu, Yoji ^a   Doizaki, Masao ^a   Hayashi, Kazuhiko ^a   Ishigami, Masatoshi ^a   Itoh, Akihiro ^a   Hirooka, Yoshiki ^a   Nakano, Isao ^a   Urano, Fumihiro ^b   Yoshioka, Kentaro ^c   Toyoda, Hidenori ^d   Kumada, Takashi ^d   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Elderly patient; Hepatitis C virus; Peginterferon; Ribavirin; Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM BLEEDING; FATIGUE; FEMALE; GENOTYPE; GERIATRIC PATIENT; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RNA ANALYSIS; SEX DIFFERENCE; THROMBOCYTE COUNT; VIRUS LOAD;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; PROBABILITY; PROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950599137     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02064.x     Document Type: Article

References (27)

1. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002, 62((Suppl. 1)):8-17.
2. Marcellin P, Boyer N, Gervais A. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997, 127:875-81.
3. Shiratori Y, Imazeki F, Moriyama M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517-24.
4. Ikeda K, Saitoh S, Arase Y. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999, 29:1124-30.
5. Yoshida H, Shiratori Y, Moriyama M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999, 131:174-81.
6. Imai Y, Kawata S, Tamura S. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998, 129:94-9.
7. Lai MY, Kao JH, Yang PM. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996, 111:1307-12.
8. Mchutchison JG, Gordon SC, Schiff ER. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-92.
9. Poynard T, Marcellin P, Lee SS. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-32.
10. Manns MP, Mchutchison JG, Gordon SC. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-65.
11. Arase Y, Ikeda K, Suzuki F. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007, 50:16-23.
12. Veldt BJ, Heathcote EJ, Wedemeyer H. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147:677-84.
13. Bresci G, Del Corso L, Romanelli AM, Giuliano G, Pentimone F. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc 1993, 41:857-62.
14. Horiike N, Masumoto T, Nakanishi K. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995, 10:246-9.
15. Iwasaki Y, Ikeda H, Araki Y. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006, 43:54-63.
16. Hiramatsu N, Oze T, Tsuda N. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 2006, 35:185-9.
17. Honda T, Katano Y, Urano F. Efficacy of ribavirin plus interferon-alpha in patients aged > or =60 years with chronic hepatitis C. J Gastroenterol Hepatol 2007, 22:989-95.
18. Antonucci G, Longo MA, Angeletti C. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007, 102:1383-91.
19. Ohno O, Mizokami M, Wu RR. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997, 35:201-7.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-93.
21. Imai Y, Kasahara A, Tanaka H. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004, 39:1069-77.
22. Yoshida H, Arakawa Y, Sata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002, 123:483-91.
23. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004, 11:243-50.
24. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82.
25. Poynard T, Mchutchison J, Goodman Z, Ling MH, Albrecht J. Is an " a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000, 31:211-8.
26. Sezaki H, Suzuki F, Kawamura Y. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009, 52:43-8.
27. Poynard T, Ratziu V, Charlotte F, Goodman Z, Mchutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34:730-9.